The aim of this study was to prepare ODT of taste masked levocetrizine dihydrochloride by using ion exchange resin. Levocetrizine Dihydrochloride is bitter in taste, Kyron T-134 a weak cationic exchange resin was used to mask the bitter taste of the drug. The ODTs were prepared by using drug-resin (DRC) complex using batch process. Compression of ODTs was done by using direct compression method with the technique of addition of superdisintegrants. Central composite design (CCD) was applied as an optimization technique. FTIR and DSC studies indicated drug and excipients were compatible with each other. The prepared orodispersible tablet blend and tablets were evaluated for various pre-compression and post-compression parameters. The Batch LH3 was given as optimized batch by central composite design. This optimized batch LH3 was passed all the pre-compression and post- compression parameters. The prepared ODTS showed successfully rapid onset of action with decrease in disintegration time 26 sec and %drug released was found to be 98.26%. It was concluded that levocetrizine dihydrochloride ODTs were prepared successfully by taste masking method using Kyron T-134 ion exchange resin and croscarmellose sodium as Superdisintegrant using CCD. AS per CDER guidelines, it shows DT within 5-30 sec.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.